GlassScriptPhysician profile
Sharon Shiraga
NPI 1447411954
$28,428.40
in general payments reported to CMS, 2019-2025
17 companies · $18K in 2025
The $18K reported for 2025 was more than what 97% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $24.09 · 2022: $168 · 2023: $1,913 · 2024: $8,240 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $15K · Food and Beverage: $6,646 · Travel and Lodging: $4,730 · Consulting Fee: $1,074 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $15,000.00 |
| Food and Beverage | $6,646.08 |
| Travel and Lodging | $4,729.80 |
| Consulting Fee | $1,074.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $21,493.36 | 2019-2025 | Davinci Xi, Da Vinci Surgical System |
| Medtronic, INC. | $3,292.31 | 2022-2025 | Signia, Progrip, Absorbatack |
| Astrazeneca Pharmaceuticals LP | $1,074.00 | 2025 | Imfinzi |
| Phathom Pharmaceuticals, INC. | $682.56 | 2024-2025 | Voquezna |
| Davol INC. | $641.10 | 2024-2025 | Phasix Mesh, Arista Ah Flexitip, Arista |
| Aroa Biosurgery Incorporated | $218.92 | 2025 | |
| Gilead Sciences, INC. | $200.00 | 2025 | |
| W. L. Gore & Associates, INC. | $154.64 | 2024 | Gore Synecor Biomaterial |
| Madrigal Pharmaceuticals | $142.08 | 2024 | Rezdiffra |
| Vertex Pharmaceuticals Incorporated | $124.50 | 2025 | |
| Evoendo, INC | $120.18 | 2025 | |
| Covidien LP | $89.82 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $58.85 | 2024 | Alphaone |
| Cumberland Pharmaceuticals, INC. | $54.99 | 2025 | Caldolor |
| On Target Laboratories, INC | $45.00 | 2025 | Cytalux |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $31.90 | 2023 | Linx Reflux Management System |
| Endogastric Solutions, INC | $4.19 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Shiraga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.